38583-85-6Relevant academic research and scientific papers
METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION
-
Page/Page column 42, (2016/06/28)
The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.
METHOD OF PROVIDING OCULAR NEUROPROTECTION
-
Paragraph 0169, (2014/09/30)
Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine deri
METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
-
Page/Page column 32; 33, (2010/11/17)
Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need t
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor
Vittori, Sauro,Lorenzen, Anna,Stannek, Christina,Costanzi, Stefano,Volpini, Rosaria,Ijzerman, Adriaan P.,Von Frijtag Drabbe Kunzel, Jakobien K.,Cristalli, Gloria
, p. 250 - 260 (2007/10/03)
A number of cycloalkyl substituents (from C-3 to C-8) have been introduced on the 6-amino group of adenosine, 1-deazaadenosine, and 2'- deoxyadenosine, bearing or not a chlorine atom at the 2-position, to evaluate the influence on the A1 and A(
Anti-dementia agents
-
, (2008/06/13)
An anti-dementia agent comprising as an active ingredient an adenosine derivative is disclosed. The anti-dementia agent is useful in the therapy of various types of dementia, especially senile dementia. Examples of the adenosine derivative include L-N6 -phenylisopropyl-adenosine, 2-chloroadenosine, N6 -cyclohexyladenosine, adenosine-5'-(N-cyclopropyl)carboxamide.
